These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 21441754)

  • 1. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin-based therapies in type 2 diabetes: a review of clinical results.
    Bosi E; Lucotti P; Setola E; Monti L; Piatti PM
    Diabetes Res Clin Pract; 2008 Dec; 82 Suppl 2():S102-7. PubMed ID: 19022515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of incretin based therapies].
    Gallwitz B
    Dtsch Med Wochenschr; 2009 May; 134(20):1062-6. PubMed ID: 19421931
    [No Abstract]   [Full Text] [Related]  

  • 6. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S; Raccah D; Schweizer A; Dejager S
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin physiology and its role in type 2 diabetes mellitus.
    Svec F
    J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT
    J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 11. Choosing among the incretin agents and why it matters.
    Unger J
    J Fam Pract; 2010 May; 59(5 Suppl):S30-5. PubMed ID: 20544056
    [No Abstract]   [Full Text] [Related]  

  • 12. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S5-9. PubMed ID: 20824239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolic syndrome influences the response to incretin-based therapies.
    Fadini GP; de Kreutzenberg SV; Gjini R; Avogaro A
    Acta Diabetol; 2011 Sep; 48(3):219-25. PubMed ID: 21574000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP-4 inhibitors: what may be the clinical differentiators?
    Gerich J
    Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing type 2 diabetes in the primary care setting: beyond glucocentricity.
    Kuritzky L
    Am J Med Sci; 2010 Aug; 340(2):133-43. PubMed ID: 20571352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
    Dejager S; Schweizer A
    Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.